Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHUSPAN: Corticosteroids and Adjunctive Therapy in PAN and MPA
NCT00400075Phase 4
Key facts
- Status
- Unknown
- Start
- Jul 1996
- Countries
- 1
- Sponsor
- Hospices Civils de Lyon
- Modality
- Small Molecules
- Conditions
- polyarteritis nodosa (PAN)microscopic polyangiitis (MPA)
01
Overview
Phase 4, randomised trial in polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) comparing Azathioprine with Cyclophosphamide (2 arms). Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Design
2 arms- Study design
- Randomized
Azathioprine
6 months of oral azathioprine (2mg/kg/day) as adjunctive therapy.
Cyclophosphamide
6 cyclophosphamide pulses (0.6g/m2 D1, D15, D30 then every month) as adjunctive therapy.
03
Who it enrols
Patients >= 15 years with newly diagnosed polyarteritis nodosa or microscopic polyangiitis without poor prognostic factors (FFS=0). Excludes those with prior systemic vasculitis treatment, history of cancer, HIV, HBV, HCV, or psychiatric disorders.
04
Endpoints
Primary
Disease-Free Survival
Secondary
Overall Survival
Relapse Rate
Adverse Events
Beyond the preview
Go deeper on NCT00400075.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400075.